SCHEMBL29888274

SCHEMBL29888274

Cc1c(F)ccc([N+](=O)[O-])c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.50
ATM Q13315 1/20 0.50
ALDH1A1 P00352 3/20 0.48
HIF1A Q16665 2/20 0.48
TSHR P16473 9/20 0.47
CYP3A4 P08684 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
VCAM1 P19320 1/20 0.46
CASP6 P55212 1/20 0.44
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 1/20 0.41
POLB P06746 1/20 0.40
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
CYP1A2 P05177 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL574038 1.00 TDP1 (0.50) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL29788829 0.87 TDP1 (0.56) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL1424697 0.87 TDP1 (0.56) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL1636077 0.86 TDP1 (0.60) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL29902915 0.85 TDP1 (0.54) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL2481319 0.85 TDP1 (0.54) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL3634865 0.83 TSHR (0.55) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL29361654 0.82 TDP1 (0.54) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL57498 0.82 TDP1 (0.54) TDP1ATMALDH1A1HIF1ATSHR
SCHEMBL31462805 0.82 TDP1 (0.52) TDP1ATMALDH1A1HIF1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 CN disclosed
CN-118459485-A Amino-substituted heterocycles for the treatment of cancers with EGFR mutations 纽威伦特公司 2024-08-09 CN disclosed
CN-117586265-A Nitrogen-containing heterocyclic compound, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-02-23 CN disclosed
EP-4323356-A1 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS Nuvalent, Inc. (US) 2024-02-21 EP disclosed
CN-117500803-A Amino-substituted heterocycles for the treatment of cancers with EGFR mutations 纽威伦特公司 2024-02-02 CN disclosed
WO-2022221227-A9 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS NUVALENT, INC. (US) 2023-11-30 WO disclosed
EP-4267137-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2023-11-01 EP disclosed
CN-110740991-B Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2023-07-04 CN disclosed
CN-113614087-B WEE1 inhibitor and preparation and application thereof 首药控股(北京)股份有限公司 2023-06-02 CN disclosed
CN-115996917-A 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors 艾捷斯治疗公司 2023-04-21 CN disclosed
EP-4146639-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2023-03-15 EP disclosed
WO-2022269531-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-12-29 WO disclosed
EP-4077316-A1 BENZIMIDAZOLE DERIVATIVES Pfizer Inc. (US) 2022-10-26 EP disclosed
WO-2022221227-A1 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS NUVALENT, INC. (US) 2022-10-20 WO disclosed
CN-115087655-A Benzimidazole derivatives 辉瑞公司 2022-09-20 CN disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed